IP Verse

Lipidomic Biomarkers For Atherosclerosis And Cardiovascular Disease - EP2567240

The patent EP2567240 was granted to Zora Biosciences on Mar 3, 2021. The application was originally filed on May 5, 2011 under application number EP11719802A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2567240

ZORA BIOSCIENCES
Application Number
EP11719802A
Filing Date
May 5, 2011
Status
Patent Maintained As Amended
Jan 29, 2021
Grant Date
Mar 3, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

METANOMICS HEALTHJan 4, 2019ALTMANN STOSSEL DICK PATENTANWALTE PARTG MBBWITHDRAWN

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2007099242
DESCRIPTIONUS2008085939
DESCRIPTIONWO2004003838
DESCRIPTIONWO2008001194
DESCRIPTIONWO2008148857
INTERNATIONAL-SEARCH-REPORTCN101522910
INTERNATIONAL-SEARCH-REPORTUS2004143461
INTERNATIONAL-SEARCH-REPORTUS2009029473
INTERNATIONAL-SEARCH-REPORTUS2009197242
INTERNATIONAL-SEARCH-REPORTWO2004085610
INTERNATIONAL-SEARCH-REPORTWO2007127192
OPPOSITIONUS2009197242
OPPOSITIONWO2008118413
OPPOSITIONWO2011063470

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "Cer(d18:1/18:0)", LMSD, Database accession no. LMSP02010006
OPPOSITION- LMGP01010585, Database accession no. LMSD
OPPOSITION- LMSD, Database accession no. LMSP02010007
OPPOSITION- MIETTINEN et al., "Fatty-acid composition of serum lipids predicts myocardial infarction", Br Med J (Clin Res Ed), (19821009), vol. 285, no. 6347, pages 993 - 996, XP009107411
OPPOSITION- "Part 1 / Autopsy Techniques", Jurgen Ludwig, Handbook of Autopsy Practice, (20020000), page 114, XP055549856
OPPOSITION- S upplementary Data of D18
OPPOSITION- MULLER-HENNESSEN et al., "Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise : Metabolic profiles in heart failure", ESC Heart Failure, (20170501), vol. 4, no. 2, pages 178 - 189, XP055550358
OPPOSITION- LIN et al., "Silent myocardial ischemia is associated with altered plasma phospholipids.", Journal of Clinical Laboratory Analysis, (20090000), vol. 23, pages 45 - 50, XP055549888
OPPOSITION- ICHI et al., "Association of Ceramides in Human Plasma with Risk Factors of Atherosclerosis", Lipids, (20140000), vol. 41, pages 859 - 863, XP055549880
OPPOSITION- Darae, "eSuppl Table: Complete list of 217 metabolites; multivariable-adjusted risk of incident AF", HHS Public Access Author Manuscript, pages 1 - 8, XP055549825
OPPOSITION- DARAE KO et al., "Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart Study)", HHS Public Access Author Manuscript, (20161115), vol. 118, no. 10, pages 1493 - 1496, XP055549818
OPPOSITION- PAAPSTEL et al., "Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis", Nutr Metab Cardiovasc Dis, (20180100), vol. 28, no. 1, pages 44 - 52, XP085315117
OPPOSITION- Paapstel et al., "Supplementary Material Metabolic quantitation and quality control to Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis", NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASE, (20180100), vol. 28, pages 1 - 5, XP055550360
OPPOSITION- WILENSKY et al., "Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development", Nat Med., (20080921), vol. 14, no. 10, pages 1059 - 1066, XP055049242
OPPOSITION- MEIKLE et al., "Plasma Lipidomic Analysis of Stable and Unstable Coronary Artery Disease", Arterioscler Thromb Vasc Biol., (20110000), vol. 31, pages 2723 - 2732, XP055549783
OPPOSITION- STEGEMANN et al., "Comparative Lipidomics Profiling of Human Atherosclerotic Plaques", Circ Cardiovasc Genet., (20110000), vol. 4, pages 232 - 242, XP055353615
OPPOSITION- STEGEMANN et al., "Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study", Circulation., (20140000), vol. 129, pages 1821 - 1831, XP055133138
OPPOSITION- EKROOS K et al., "Charting molecular composition of phosphatidylcholines by fatty acid scanning and ion trap MS3 fragmentation", J Lipid Res, (20030000), vol. 44, pages 2181 - 2192, XP055549862
OPPOSITION- SALATZKI J. et al., "Adipose tissue ATGL modifies the cardiac lipidome in pressure-overload-induced left ventricular failure", PLoS Genet, vol. 14, no. 1, (20180000), pages 1 - 24, URL: https://doi.org/10.1371/journal.pgen.1007171, XP055549833
OPPOSITION- FERNANDEZ C et al., "Plasma Lipid Composition and Risk of Developing Cardiovascular Disease", PLoS ONE, (20130000), vol. 8, no. 8, pages 1 - 8, XP055549845
OPPOSITION- Fernandez et al., "Supplementary Table S2. Absolute levels of the lipid species", Plos One, (20130815), pages 1 - 4, XP055551018

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents